KPIs & Operating Metrics(New)

Balance Sheet

Accounts Payables Accumulated Expenses Assets Buildings Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Curent Deferred Tax Liability Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Deferred Tax Assets Current Taxes Dividends payables Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Land & Improvements Liabilities and Shareholders Equity Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deferred Tax Liability Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Pension Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Pfizer (PFE) Liabilities from Discontinued Operations (2018 - 2019)

Pfizer has reported Liabilities from Discontinued Operations over the past 6 years, most recently at 2413000000.0 for Q4 2019.

Quarterly Liabilities from Discontinued Operations rose 27.67% to 2413000000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was 2413000000.0 through Dec 2019, up 27.67% year-over-year, with the annual reading at 2413000000.0 for FY2019, 27.67% up from the prior year.
Liabilities from Discontinued Operations was 2413000000.0 for Q4 2019 at Pfizer, up from 2009000000.0 in the prior quarter.
Over five years, Liabilities from Discontinued Operations peaked at 2413000000.0 in Q4 2019 and troughed at 1890000000.0 in Q4 2018.